Overview

  • Product nameAnti-RANKL antibody [IK22/5] (Biotin)
    See all RANKL primary antibodies
  • Description
    Rat monoclonal [IK22/5] to RANKL (Biotin)
  • ConjugationBiotin
  • Tested applicationsSuitable for: Flow Cytmore details
  • Species reactivity
    Reacts with: Mouse
  • Immunogen

    NSO derived recombinant Mouse RANKL.

  • Positive control
    • BALB/c splenocytes and Mouse RANKL transfected cells

Properties

Applications

Our Abpromise guarantee covers the use of ab95720 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Flow Cyt Use 0.125-0.25µg for 105-8 cells. A final volume of 100 µL is recommended for staining the cell sample.



ab18445-Rat monoclonal IgG2a, is suitable for use as an isotype control with this antibody.

Target

  • FunctionCytokine that binds to TNFRSF11B/OPG and to TNFRSF11A/RANK. Osteoclast differentiation and activation factor. Augments the ability of dendritic cells to stimulate naive T-cell proliferation. May be an important regulator of interactions between T-cells and dendritic cells and may play a role in the regulation of the T-cell-dependent immune response. May also play an important role in enhanced bone-resorption in humoral hypercalcemia of malignancy.
  • Tissue specificityHighest in the peripheral lymph nodes, weak in spleen, peripheral blood Leukocytes, bone marrow, heart, placenta, skeletal muscle, stomach and thyroid.
  • Involvement in diseaseDefects in TNFSF11 are the cause of osteopetrosis autosomal recessive type 2 (OPTB2) [MIM:259710]; also known as osteoclast-poor osteopetrosis. Osteopetrosis is a rare genetic disease characterized by abnormally dense bone, due to defective resorption of immature bone. The disorder occurs in two forms: a severe autosomal recessive form occurring in utero, infancy, or childhood, and a benign autosomal dominant form occurring in adolescence or adulthood. Autosomal recessive osteopetrosis is usually associated with normal or elevated amount of non-functional osteoclasts. OPTB2 is characterized by paucity of osteoclasts, suggesting a molecular defect in osteoclast development.
  • Sequence similaritiesBelongs to the tumor necrosis factor family.
  • Post-translational
    modifications
    The soluble form of isoform 1 derives from the membrane form by proteolytic processing (By similarity). The cleavage may be catalyzed by ADAM17.
  • Cellular localizationCytoplasm; Secreted and Cell membrane.
  • Information by UniProt
  • Database links
  • Alternative names
    • CD254 antibody
    • hRANKL2 antibody
    • ODF antibody
    • OPGL antibody
    • OPTB2 antibody
    • Osteoclast differentiation factor antibody
    • Osteoprotegerin ligand antibody
    • RANKL antibody
    • Receptor activator of nuclear factor kappa B ligand antibody
    • Receptor activator of nuclear factor kappa-B ligand antibody
    • sOdf antibody
    • TNF related activation induced cytokine antibody
    • TNF-related activation-induced cytokine antibody
    • TNF11_HUMAN antibody
    • TNFSF 11 antibody
    • Tnfsf11 antibody
    • TRANCE antibody
    • Tumor necrosis factor (ligand) superfamily member 11 antibody
    • Tumor necrosis factor ligand superfamily member 11 antibody
    • Tumor necrosis factor ligand superfamily member 11, soluble form antibody
    see all

Anti-RANKL antibody [IK22/5] (Biotin) images

  • Staining of 3 day unstimulated (left) and 3 day ConA activated (right) BALB/c splenocytes with 0.125 µg of Biotin Rat IgG2a Isotype Control (open histogram) or 0.125 µg of ab95720 (filled histogram) followed by Streptavidin PE. Total viable cells were used for analysis.

References for Anti-RANKL antibody [IK22/5] (Biotin) (ab95720)

This product has been referenced in:
  • Vondenhoff MF  et al. LTbetaR signaling induces cytokine expression and up-regulates lymphangiogenic factors in lymph node anlagen. J Immunol 182:5439-45 (2009). IF . Read more (PubMed: 19380791) »
  • Kamijo S  et al. Amelioration of bone loss in collagen-induced arthritis by neutralizing anti-RANKL monoclonal antibody. Biochem Biophys Res Commun 347:124-32 (2006). Flow Cyt . Read more (PubMed: 16815304) »

See all 2 Publications for this product

Product Wall

There are currently no Abreviews or Questions for ab95720.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"